Business Context and Reporting Period
This Form 8-K is a current report filed by Leap Therapeutics, Inc. (not Cypherpunk Technologies Inc.) on June 17, 2020. The registrant is a Delaware corporation with principal executive offices in Cambridge, MA, and its common stock trades on the Nasdaq Global Market under the symbol LPTX. The company is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, or cash flow data. However, it discloses specific transaction metrics related to a terminated equity offering program:
- Shares Sold: 1,033,147 shares of Common Stock were sold under the terminated Distribution Agreement.
- Net Proceeds: Approximately $1,922,842 were generated from the sales under the terminated agreement.
- Program Capacity: The terminated agreement allowed for aggregate gross sales proceeds of up to $30 million.
Material Changes
The filing reports two material events occurring on June 17, 2020:
- Termination of Material Definitive Agreement: The Company terminated its "at the market" Distribution Agreement with Raymond James & Associates, Inc., which was originally entered into on September 7, 2018.
- Proposed Capital Raise: The Company announced a proposed underwritten public offering of its Common Stock and pre-funded warrants to purchase shares of Common Stock.
Guidance, Outlook, and Risks
The filing indicates a strategic shift in capital raising methods, moving from an "at the market" program to a proposed underwritten public offering. No specific financial guidance, revenue outlook, or detailed risk factors are provided in this specific document. The full text of the press release regarding the proposed offering is referenced as Exhibit 99.1.
Investor Verification Checklist
- Verify the terms and pricing of the proposed underwritten public offering announced on June 17, 2020 (refer to Exhibit 99.1).
- Confirm the total capital raised to date versus the company's cash burn rate and runway, as this filing only details proceeds from the terminated program.
- Review the pre-funded warrant terms included in the proposed offering to understand potential dilution.
- Check subsequent filings to confirm if the proposed underwritten offering was completed and the final proceeds received.